Matthew R. Cooperberg, MD, MPH
Associate Professor, Department of Urology, UCSF
Helen Diller Family Chair in Urology, UCSF
Cancer Center Program MembershipsProstate Cancer
Both clinician and patient decisions influence the choices about the type of treatment a patient will receive for localized prostate and kidney (renal) cancer. Matthew Cooperberg, MD, MPH is conducting an ongoing research program to study national prostate cancer management trends, based on data from CaPSURE and other sources. His analyses have looked at changes in cancer risk over time, testing and treatment for prostate cancer, local variation in treatment, and the impact of socio-demographic factors on type of treatment and outcomes. Through the creation of a San Francisco General Hospital (SFGH) prostate cancer patient registry, preliminary analysis show that low socioeconomic status patients are treated for a higher percentage of high-risk disease than patients with a higher socioeconomic status. Using data from CaPSURE, the NCDB, SFGH and in collaboration with the Urologic Diseases in America project he continues to explore these topic in depth.
Prostate Cancer Risk Assessment and Comparative Effectiveness Research
Properly treating prostate cancer requires determining how likely is it that the cancer will progress. Cooperberg led the team that developed the UCSF-CAPRA score, a prostate cancer risk assessment tool that has been validated in several multi-institutional studies in the U.S. and Europe. CAPRA predicts biochemical recurrence-free survival (PSA level does not rise) after radical prostatectomy with an accuracy at least as good as more mathematically complex nomograms that require complex tables or computer software to calculate and other risk assessment instruments. The score is easy to calculate, and can be used to predict an individual's likelihood of metastasis, cancer-specific mortality, and overall mortality after treatment by surgery, radiation therapy, or androgen deprivation therapy.
Cooperberg is currently developing a post-operative extension of the CAPRA score (CAPRA-S). After surgery additional information is available from the pathologist's analysis of the removed prostate. This information can help identify men who will benefit from additional therapy such as radiation and/or hormonal therapy after surgery. CAPRA-S will help in that decision making process. Cooperberg is also collaborating with a group of Japanese scientist to develop a prediction instrument specifically applicable to high-risk patients and patients receiving androgen deprivation therapy (J-CAPRA). As new biomarkers, such as genomic and advanced imaging data, are proven valid by UCSF Urology and collaborating laboratory investigators, Cooperberg plans to integrate the information into the current standard measures of risk and outcomes to improve risk assessment. These findings will help men determine with greater confidence whether active surveillance, surgery, radiation, hormonal therapy, or some combination may be most appropriate for them.
Because accurate risk assessment is essential to compare the effectiveness of different prostate cancer treatments, Cooperberg is currently conducting such comparison studies using CaPSURE data. These data will provide a unique source of insight for future comparative effectiveness research.
Cooperberg is collaborating on a project that will lead to better clinical care for cancer survivors. His efforts have helped to develop UCSF’s Urologic Oncology Database (UODB) into a comprehensive data repository for clinical information about patients treated for prostate, bladder, and renal cancers. With the Urology Department’s information experts Cooperberg is developing an automated process to further augment UODB by automatically transferring data from the UCSF Medical Center’s information system into UODB. In collaboration with UCSF Breast Oncology and a health care web services company Cooperberg is developing an electronic survey for cancer patients. Patients will complete a health history and health-related quality of life (HRQOL) survey prior to their first visit to the clinic and at defined intervals after treatment. This effort is expected to help patients and clinicians track HRQOL outcomes, such as urinary and sexual function, after treatment. The survey will help physicians to identify those patients who may need to be seen in clinic more or less frequently.
Small Renal Masses
In collaboration with the laboratory of John Kurhanewicz, PhD, Cooperberg is conducting a study to see if magnetic resonance spectroscopy (MRS) can be used to non-invasively diagnosis small renal tumors. MRS is a specialized technique associated with magnetic resonance imaging (MRI). MRS equipment can be used to pick up signals from different chemical nuclei within the body. A preliminary laboratory study is using tissue to identify the specific MRS signals associated with a variety of renal tumors. Once renal tumor signals have been identified, Cooperberg plans to test the ability of MRS to accurately analyze renal tumors in patients. This will be done by using MRS imaging technology on patients who are already scheduled for renal cancer surgery prior to their operation. The pre and post surgery information can be analyzed to determine if the information collected non-invasively by the MRS technology matches the histology and grade of the actual tumor.
Dartmouth College, Hanover, NH, BA, 1991-95, English
Yale University, New Haven, CT, MD, MPH, 1995-00, Medicine, Health Policy
Internship in General Surgery (preliminary to Urology), Yale University, New Haven, CT
Research Fellowship in Genitourinary Oncology, University of California, San Francisco, CA
Residency in Urology, University of California, San Francisco, CA
Clinical Fellow, Genitourinary Oncology, University of California, San Francisco, CA
Assistant Professor, Department of Urology, University of California, San Francisco, CA
Associate Professor, Department of Urology, University of California, San Francisco, CA
Honors & Awards
College honors: summa cum laude, Phi Beta Kappa, high honors in major, Presidential Scholar, Rufus Choate Scholar, B. William Hochman Prize in American Literature
American Cancer Society Research Fellowship
AMA John Conley Ethics Essay Contest, honorable mention
UCSF Prostate Cancer Research Symposium, 2nd place, Clinical Research
UCSF Prostate, Breast, Prostate SPORE Scientific Retreat, honorable mention, Clinical Research
Northern California Urology Resident Research Symposium, 1st place, Clinical Research
Northern California Urology Resident Research Symposium, 3rd place, Clinical Research
AUA Gerald P. Murphy Prostate Scholar
Northern California Urology Resident Research Symposium, 2nd place, Clinical Research
Western Section AUA Miley B. Wesson Resident Essay Contest, 3rd place
Society of Urologic Oncology Poster Session, 3rd place overall
Western Section AUA Miley B. Wesson Resident Essay Contest, 3rd place
Western Section AUA Poster Session I, 1st place
2016 physician award, Marin Prostate Cancer Information and Support Group
- (2005 - present)
- Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ, Chan JM, Anast JW, Carroll PR, Kane CJ. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology 66(5):1060, 2005
- Camargo AH, Cooperberg MR, Ershoff BD, Rubenstein JN, Meng MV, Stoller ML. Laparoscopic management of peripelvic renal cysts: University of California, San Francisco, experience and review of literature. Urology 65(5):882, 2005
- Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, DuChane J, Carroll PR. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173(6):1938, 2005
- Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol 23(32):8146, 2005
- Latini DM, Elkin EP, Cooperberg MR, Sadetsky N, Duchane J, Carroll PR. Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE. Cancer 106(4):789, 2006
- Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC, Jr., Amling CL, Terris MK, Aronson WJ, Kane CJ, Carroll PR. Multiinstitutional validation of the UCSF Cancer of the Prostate Risk Assessment for prediction of recurrence after radical prostatectomy. Cancer 107(10):2384, 2006
- Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178(3 Pt 2):S14, 2007
- Cooperberg MR, McAninch JW, Alsikafi NF, Elliott SP. Urethral reconstruction for traumatic posterior urethral disruption: outcomes of a 25-year experience. J Urol 178(5):2006, 2007
- Cooperberg MR, Modak S, Konety BR. Trends in regionalization of inpatient care for urological malignancies, 1988 to 2002. J Urol 178(5):2103, 2007
- Whitson JM, Cooperberg MR, Stackhouse GB, Stoller ML. Urinary citrate levels do not correlate with urinary pH in patients with urinary stone formation. Urology 70(4):634, 2007
- Cooperberg MR, Duh QY, Stackhouse GB, Stoller ML. Oral calcium supplementation associated with decreased likelihood of nephrolithiasis prior to surgery for hyperparathyroidism. Int J Urol 14(12):1113, 2007
- Cooperberg MR. The art and science of risk stratification in localized prostate cancer. Semin Prev Altern Med 3(2):101, 2007.
- Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE, Jr., Wallace ME, Kantoff PW, Carroll PR. Active surveillance for early-stage prostate cancer: review of the current literature [review]. Cancer 112(8):1650, 2008
- Cooperberg MR, Villalta JD, Kane CJ, Richey J, Stuart AK, Carroll PR. Decreasing size at diagnosis among stage I renal cell carcinomas: analysis from the National Cancer Data Base, 1993-2003. J Urol 179(6):2131, 2008.
- Cooperberg MR, Cowan J, Broering JM, Carroll PR. High-risk prostate cancer in the United States, 1990-2007. World J Urol 26(3):211, 2008
- Dall'era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 112(12):2664, 2008
- Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 113(1):78, 2008
- Wu AK, Cooperberg MR, Sadetsky N, Carroll PR. Health related quality of life in patients treated with multimodal therapy for prostate cancer. J Urol 180(6):2415-22, 2008
- Cooperberg MR. Prostate cancer risk assessment: choosing the sharpest tool in the shed [editorial]. Cancer 113(11):3062-66, 2008
- Odisho AY, Fradet V, Cooperberg MR, Ahmad AE, Carroll PR. Geographic distribution of urologists throughout the United States using a county level approach. J Urol 181(2):760-5; discussion 65-6, 2009
- Konety BR, Cooperberg MR, Carroll PR. Are age-based criteria the best way to determine eligibility for prostate cancer screening? [letter]. Ann Intern Med 150(3):220-1, 2009
- Berger AD, Wu W, Eisner BH, Cooperberg MR, Duh QY, Stoller ML. Patients with primary hyperparathyroidism--why do some form stones? J Urol 181(5):2141-5, 2009
- Breyer BN, Cooperberg MR, McAninch JW, Master VA. Improper retrograde urethrogram technique leads to incorrect diagnosis. J Urol 182(2):720-21, 2009
- Cooperberg MR, Konety BR. Management of localized prostate cancer in men over 65 years [review]. Curr Opin Urol 19(3):309-14, 2009
- Cooperberg MR, Porter MP, Konety BR. Candidate quality of care indicators for localized bladder cancer [review]. Urol Oncol 27(4):435-42, 2009
- Cooperberg MR, Birkmeyer JD, Litwin MS. Defining high quality health care [review]. Urol Oncol 27(4):411-16, 2009
- Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 101(12):878-87, 2009
- Cooperberg MR, Carroll PR. Prostate-cancer screening [letter]. N Engl J Med 361(2):203; author reply 04-5, 2009
- Eisenberg ML, Davies BJ, Cooperberg MR, Cowan JE, Carroll PR. Prognostic implications of an undetectable ultrasensitive prostate specific antigen level after radical prostatectomy. Eur Urol, epub ahead of print.